Mechanism of Action and Main Targets
Thiazolidinediones exert their effects at the intracellular level. Their primary target is the nuclear PPAR receptors (peroxisome proliferator-activated receptors). These structures are localized in the nuclei of cells in insulin-dependent tissues, predominantly in adipocytes. The main function of PPAR receptors is to regulate the transcription of genes responsible for lipid and carbohydrate metabolism.
There are two main types of PPAR receptors targeted by thiazolidinediones, each triggering specific effects:
- PPAR-$\gamma$ (gamma): Regulate adipocyte differentiation processes, strictly control adipogenesis, and regulate fatty acid accumulation in cells. A key effect of their activation is the stimulation of glucose transporter synthesis (GLUT-4) and their translocation into cell membranes.
- PPAR-$\alpha$ (alpha): Responsible for regulating lipid metabolism, specifically fatty acid oxidation. Additionally, they influence the metabolism of inflammatory mediators (prostaglandins) by stimulating the synthesis of the COX-2 enzyme.
Pharmacodynamic Effects
The key effect of thiazolidinediones is combating insulin resistance. The drugs act as PPAR-$\gamma_2$ receptor agonists. Consequently, they increase the population of small adipocytes, which possess significantly higher insulin sensitivity compared to large fat cells.
Effects on carbohydrate metabolism are mediated through two parallel mechanisms:
- Increasing the number of insulin-dependent glucose transporters (GLUT-4), which facilitates glucose transport into the cell.
- Decreasing plasma concentrations of free fatty acids and glycerol (under normal conditions, an excess of these substances prevents adequate tissue glucose uptake).
Beyond metabolic effects, thiazolidinediones affect the vascular wall and slow down the progression of atherosclerosis. This mechanism is linked to PPAR-$\alpha$ agonism, which accelerates the catabolism of inflammatory mediators, decreases atherogenic lipoproteins, and concurrently increases anti-atherogenic high-density lipoproteins (HDL) in the plasma.
Pharmacokinetics and Clinical Use of Pioglitazone
The primary representative of this group is pioglitazone (Pioglitazone, known trade names Actos and Pioglar). Other agents in this class include rosiglitazone (Rosiglitazone, Avandia) and troglitazone (Troglitazone).
Pharmacokinetic parameters of pioglitazone:
- Absorption: Rapid; the drug enters systemic circulation within 30 minutes of administration.
- Peak Concentration ($C_{max}$): Reached in the blood within 2 hours.
- Duration of Action: Therapeutically high concentration persists for about 24 hours.
- Metabolism: Occurs in the liver via the cytochrome P450 system, producing two active metabolites.
- Excretion: Unchanged pioglitazone is excreted via bile. Its metabolites leave the body via the intestines and kidneys (renal excretion accounts for 15–30%).
- Half-life ($t_{1/2}$): 3–7 hours for pioglitazone itself, and 16 to 24 hours for its active metabolites.
Due to its long duration of action, pioglitazone has a convenient once-daily dosing regimen. In clinical practice, it is used both as monotherapy and in combination therapy. Pioglitazone is successfully combined with sulfonylureas, biguanides, and insulin preparations.
Adverse Effects
Despite their high efficacy, the use of thiazolidinediones carries a risk of adverse reactions. The main side effects include:
- Hypoglycemia (especially in combination therapy).
- Peripheral edema.
- Anemia.
- Decreased blood bilirubin and reduced liver enzyme levels.